Drugs / BRII-296
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06057012 | Sep 2023 → Mar 2024 | postpartum depression | Brii Biosciences Limited | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-09-26 | Brii Biosciences Limited | Results Brii Biosciences Announces Top-line Results from Phase 1 Study of BRII-296, A Long-Acting Therapy in Development for Postpartum Depression briibio.com ↗
Data demonstrated that a single administration of BRII-296 at 600 mg delivered a favorable pharmacokinetic profile and is safe and well-tolerated in healthy subjects |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-09-26 | Brii Biosciences Limited | Brii Biosciences Announces Top-line Results from Phase 1 Study of BRII-296, A Long-Acting Therapy in Development for Postpartum Depression briibio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BRII-296 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06057012 ↗ |
| Route | Intramuscular | “via intramuscular injection” NCT06057012 ↗ |